Idéal Investisseur
Français English
CAC 40 :
8 157,82 pts
-0.84%


Last updated : 24/04/2026 - 17h35 (last close)
Last close data
🏠 Home   ➤    Stock news

Eurofins Scientific Shares Close Above 20-Day Moving Average

Eurofins Scientific shares closed the Wednesday, January 28 session at 70.62 euros, down 0.87% from the previous day. However, the stock of the European leader in laboratory testing and analysis shows a strong momentum over the past months, with a gain of 14.68% over three months and 42.72% over one year.


Eurofins Scientific Shares Close Above 20-Day Moving Average

Technical Analysis

Technically, Eurofins Scientific is trading above its 20-day moving average, which is positioned at 69.39 euros. This positioning indicates a favorable short-term trend, despite a slight decline during the session. The stock also benefits from sustained momentum over the past week, with a progression of 0.37%. The Relative Strength Index (RSI) stands at 60, indicating some dynamism without signaling overheating. The one-month volatility is set at 9.70, which is moderate for the sector. The current technical configuration thus suggests potential for a short-term upward movement, provided that the support from the 20-day moving average continues.

Investment House Forecasts

Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
Before 9 AM every morning Euronext data AI-powered analysis

Several investment houses have recently adjusted their forecasts for the stock. Kepler Cheuvreux raised its price target from 72 to 81 euros in mid-January, representing a potential progression of 14.7% from the current level. This upward revision follows several quarters of solid operational performance as perceived by analysts. Meanwhile, Morgan Stanley also revised its valuation in early January, raising its target from 61 to 64 euros, while maintaining a market-weight recommendation. These consecutive adjustments reflect a generally positive appreciation of the stock's fundamentals by market professionals.



Sector Santé · Pharmacie Services médicaux


Assurance vie

Context

Period
  • Period: 2025
Key reported figures
  • Revenue: 7 296 M€
  • Revenue growth: 5,0%
  • EBITDA: 1 561 M€
  • EBITDA margin: 21,4%
  • Net income: 473 M€
  • Free cash flow: 876 M€
  • Net debt: 3 641 M€
  • Dividend per share: 0,72 €
Guidance from the release
  • Nous sommes satisfaits d’avoir atteint nos objectifs 2025 et de démontrer la solidité du portfolio Eurofins.
  • La performance 2025 est soutenue par la croissance organique et l’expansion des marges, avec un flux de trésorerie libre robuste et un endettement maîtrisé.

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Advertisement
Every morning
Technical market signals,
before the opening bell.
CAC 40 · SBF 120 · Signals · Analysts
🤖
Today's edition — pre-market
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Bullish signals
+5,2%
+1,8%
+0,9%
📉 Bearish signals
-14%
-5,7%
🔄 Analyst opinions
▲ 35 €
▼ 80 €
Sign up to see everything →
Before 9 AM every morning
Euronext data
AI-powered analysis





BOURSE · Chaque matin
La synthèse bourse,
avant l'ouverture.
Notre moteur analyse chaque nuit le CAC 40 et le SBF 120. Ce qui mérite attention remonte directement dans votre boîte mail. Gratuit.
Avant 9h00 1000+ inscrits 100% gratuit